Barinthus Biotherapeutics (BRNS)
NASDAQ:BRNS
Want to see BRNS full AI Analyst Report?
BRNS Stock Chart & Stats
$0.76
>-$0.01(-0.43%)
At close: 4:00 PM EST
$0.76
>-$0.01(-0.43%)
Day’s Range― - ―
52-Week Range$0.51 - $2.92
Previous CloseN/A
Volume10.26K
Average Volume (3M)124.73K
Market Cap
$28.61M
Enterprise Value-$27.62M
Total Cash (Recent Filing)$67.19M
Total Debt (Recent Filing)$11.01M
Price to Earnings (P/E)―
Beta1.89
Next Earnings
Aug 06, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.29
Shares Outstanding40,848,892
10 Day Avg. Volume97,530
30 Day Avg. Volume124,726
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)0.38
Price to Sales (P/S)0.00
P/FCF Ratio-0.59
Enterprise Value/Market Cap-0.97
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit15.67
Enterprise Value/Ebitda0.58
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.15
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance SheetA low-debt capital structure provides durable financial flexibility for a clinical-stage biotech. With modest leverage, the company can pursue capital-intensive trials, partnerships, or restructurings with lower bankruptcy risk than peers, preserving optionality during multi-year R&D timelines.
Merger And Cash RunwayThe Clywedog merger structurally reshapes the company and provides a reported cash runway through 2027. That extended liquidity horizon materially reduces near-term financing pressure, supports planned clinical readouts and increases the chance of advancing multiple programs toward value-driving milestones.
Experienced CFO AppointmentBringing in an experienced finance executive via a formal services agreement strengthens governance and financial stewardship. Durable benefits include improved capital allocation, more credible investor communications, and better structuring of financings or collaborations during critical clinical and integration phases.
Bears Say
Zero/volatile RevenueThe absence of stable commercial revenue means the business lacks recurring cash generation and is dependent on irregular sources or financings. Over time this increases execution risk, forces reliance on capital markets or partners, and magnifies dilution risk if clinical progress stalls.
Persistent Negative Cash FlowSustained negative operating and free cash flow indicate the company consumes capital to fund development without self-sustaining operations. This accelerates the need for external funding, constrains strategic choices, and can force unfavorable financing terms that erode long-term shareholder value.
Shrinking Equity / Dilution RiskEroding equity and persistently negative ROE reflect cumulative losses and capital consumption. Over the medium term this raises the probability of equity raises, contractual concessions, or asset sales, which can dilute existing holders and reduce the company’s ability to fund ambitious clinical programs independently.
Barinthus Biotherapeutics News
BRNS FAQ
What was Barinthus Biotherapeutics’s price range in the past 12 months?
Barinthus Biotherapeutics lowest stock price was $0.51 and its highest was $2.92 in the past 12 months.
What is Barinthus Biotherapeutics’s market cap?
Barinthus Biotherapeutics’s market cap is $28.61M.
When is Barinthus Biotherapeutics’s upcoming earnings report date?
Barinthus Biotherapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 50 days.
How were Barinthus Biotherapeutics’s earnings last quarter?
Barinthus Biotherapeutics released its earnings results on Apr 30, 2026. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.28 by $0.14.
Is Barinthus Biotherapeutics overvalued?
According to Wall Street analysts Barinthus Biotherapeutics’s price is currently Overvalued.
Does Barinthus Biotherapeutics pay dividends?
Barinthus Biotherapeutics does not currently pay dividends.
What is Barinthus Biotherapeutics’s EPS estimate?
Barinthus Biotherapeutics’s EPS estimate is -0.28.
How many shares outstanding does Barinthus Biotherapeutics have?
Barinthus Biotherapeutics has 40,848,892 shares outstanding.
What happened to Barinthus Biotherapeutics’s price movement after its last earnings report?
Barinthus Biotherapeutics reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.28. Following the earnings report the stock price went up 8.514%.
Which hedge fund is a major shareholder of Barinthus Biotherapeutics?
Currently, no hedge funds are holding shares in BRNS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Barinthus Biotherapeutics
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical firm, is dedicated to pioneering innovative T-cell immunotherapies. These cutting-edge treatments are engineered to harness the body's own immune system to effectively combat chronic infectious diseases, autoimmune disorders, and various cancers. The company is actively progressing a robust portfolio of experimental medicines spanning diverse medical fields. Prominent among these is VTP-300, an immunotherapeutic candidate striving to achieve a functional cure for chronic Hepatitis B virus (HBV) infection. Also in development is VTP-200, a non-surgical therapeutic option aimed at persistent high-risk human papillomavirus (HPV). For autoimmune conditions, VTP-1000 is an autoimmune candidate leveraging the proprietary SNAP-TI platform to treat celiac disease. Additionally, VTP-850 is a next-generation immunotherapeutic designed to address recurrent prostate cancer. Furthermore, the preclinical candidate VTP-1100 utilizes the SNAP-CI platform in its development as a potential treatment for HPV-related cancers. Originally established in 2016 under the name Vaccitech plc, the company rebranded to Barinthus Biotherapeutics plc in November 2023. Its main office is located in Harwell, United Kingdom.
Technical Analysis
Collplant Holdings
―
ALX Oncology Holdings
―
Aligos Therapeutics
―
CytoMed Therapeutics Limited
―
Boundless Bio Inc.
―
Ownership Overview
―
Insiders
0.03% Mutual Funds
21.69% Other Institutional Investors
78.29% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---